PTC Therapeutics, Inc.(NASDAQ : PTCT)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading PTCT News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.04%||68.55||0.9%||$505.54m|
|REGN||Regeneron Pharmaceuticals, Inc.||5.97%||388.49||2.7%||$332.95m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.69%||127.78||1.9%||$250.96m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.75%||118.30||1.9%||$235.75m|
|NBIX||Neurocrine Biosciences, Inc.||-0.36%||53.40||5.3%||$114.24m|
|BMRN||BioMarin Pharmaceutical Inc.||-0.40%||95.88||4.5%||$113.09m|
|KITE||Kite Pharma, Inc.||-0.68%||82.08||16.6%||$94.29m|
|A||Agilent Technologies, Inc.||-0.70%||55.04||1.5%||$93.33m|
|SRPT||Sarepta Therapeutics, Inc.||4.44%||36.26||19.8%||$82.73m|
PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. Its preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. It product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.